Searched for: in-biosketch:true
person:gudesm01
Multiple Sclerosis: Brain Atrophy and Computerized Cognitive Testing - A Longitudinal Investigation of Changes in Disease Impact [Meeting Abstract]
Greif, Eric; Wissemann, Karl; Fafard, Lori; Bumstead, Barbara; Buhse, Marijean; Zarif, Myassar; Gudesblatt, Mark
ISI:000577381503108
ISSN: 0028-3878
CID: 5342762
Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea
Frank, Samuel; Stamler, David; Kayson, Elise; Claassen, Daniel O; Colcher, Amy; Davis, Charles; Duker, Andrew; Eberly, Shirley; Elmer, Lawrence; Furr-Stimming, Erin; Gudesblatt, Mark; Hunter, Christine; Jankovic, Joseph; Kostyk, Sandra K; Kumar, Rajeev; Loy, Clement; Mallonee, William; Oakes, David; Scott, Burton L; Sung, Victor; Goldstein, Jody; Vaughan, Christina; Testa, Claudia M
Importance:Tetrabenazine is efficacious for chorea control; however, tolerability concerns exist. Deutetrabenazine, a novel molecule that reduces chorea, was well tolerated in a double-blind, placebo-controlled study. Objectives:To evaluate the safety and explore the efficacy of conversion from tetrabenazine to deutetrabenazine in patients with chorea associated with Huntington disease (HD). Design, Setting, and Participants:In this ongoing, open-label, single-arm study that started on December 21, 2013, 37 patients at 13 Huntington Study Group sites in the United States and Australia who were taking stable doses of tetrabenazine that provided a therapeutic benefit were switched overnight to deutetrabenazine therapy. After week 1, the deutetrabenazine dose was titrated on a weekly basis for optimal chorea control. Interventions:Deutetrabenazine administration at a dosage thought to provide comparable systemic exposure to the active metabolites of the prior, stable tetrabenazine regimen. Main Outcomes and Measures:Safety measures included adverse events (AEs), clinical laboratory tests, vital signs, electrocardiograms, and validated scales. Changes in the Unified Huntington's Disease Rating Scale total maximal chorea score and total motor score were efficacy end points. Results:Of the 53 patients with HD screened for the study, 37 ambulatory patients with manifest HD (mean [SD] age, 52.4 [11.5] years; 22 [59%] male and 15 [41%] female; 36 white [97.3%]) were enrolled. Deutetrabenazine was generally well tolerated, with low rates of neuropsychiatric AEs. Safety scales did not reveal subclinical toxicity with deutetrabenazine treatment. Rates of dose reduction or suspension attributable to AEs were also low. Chorea control, as measured by the total maximal chorea score, was maintained at week 1 and significantly improved at week 8 (mean [SD] change from baseline, 2.1 [3.2]; P < .001). Conclusions and Relevance:In patients with chorea, overnight conversion to deutetrabenazine therapy provided a favorable safety profile and effectively maintained chorea control.
PMID: 28692723
ISSN: 2168-6157
CID: 5342202
A Preliminary Investigation into the Relationship between Visual Evoked Potential Latency (VEP-L) and Outcome Parameters from Optical Coherence Tomography (OCT) in Patients With Multiple Sclerosis (PwMS) [Meeting Abstract]
Tabiri, Kojo; Srinivasan, Jared; Wissemann, Karl; Anand, Damanjyot; Fafard, Lori; Bumstead, Barbara; Buhse, Marijean; Zarif, Myassar; Gudesblatt, Mark
ISI:000577381504346
ISSN: 0028-3878
CID: 5342792
A Phase 2 Study of ADS-5102 (amantadine hydrochloride) Extended Release Capsules in Multiple Sclerosis Patients with Walking Impairment [Meeting Abstract]
Cohen, Jeffrey A.; Gudesblatt, Mark; Hunter, Samuel F.; Thrower, Ben; Brown, Theodore; Souza-Prien, Cindy; Chernoff, David; Patni, Rajiv
ISI:000395388800053
ISSN: 1352-4585
CID: 5343462
An investigation into the cognitive impact on physical disability in the community in people with multiple sclerosis (PwMS) [Meeting Abstract]
Gudesblatt, M.; Hamid, Z.; Calisi, O.; Wissemann, K.; Fafard, L.; Bumstead, B.; Buhse, M.; Zarif, M.; Blitz, K.; Srinivasan, J.; Sullivan, C.; Wilken, J.
ISI:000413730200242
ISSN: 1352-4585
CID: 5343552
An investigation into the relationship between Optical Coherence Tomography (OCT) and cognitive fatigue in people with multiple sclerosis [Meeting Abstract]
Tabiri, K.; Srinivasan, J.; Wissemann, K.; Anand, D.; Fafard, L.; Bumstead, B.; Buhse, M.; Zarif, M.; Sergott, R.; Gudesblatt, M.
ISI:000413730201156
ISSN: 1352-4585
CID: 5343562
The effectiveness of computerized screening in detecting cognitive deficits in people with multiple sclerosis [Meeting Abstract]
Wilken, J.; Gudesblatt, M.; Fratto, T.; Kane, R.; Wissemann, K.; Zarif, M.; Bumstead, B.; Fafard, L.; Topalli, I.; Buhse, M.; Blitz, K.; Golan, D.; Barbery, A.; Russell, L.; Sirikietsoong, S.; Sullivan, C.
ISI:000413730203096
ISSN: 1352-4585
CID: 5343572
Multiple sclerosis: brain atrophy and computerized cognitive testing - a cross-sectional pilot investigation [Meeting Abstract]
Gudesblatt, M.; Grief, E.; Wissemann, K.; Zarif, M.; Bumstead, B.; Fafard, L.; Buhse, M.; Golan, D.; Sullivan, C.; Doniger, G.; Wilken, J.
ISI:000413730203235
ISSN: 1352-4585
CID: 5343582
A preliminary investigation into the relationship between Visual Evoked Potential Latency (VEP-L) and outcome parameters from Optical Coherence Tomography (OCT) in people with multiple sclerosis [Meeting Abstract]
Tabiri, K.; Srinivasan, J.; Wissemann, K.; Anand, D.; Fafard, L.; Bumstead, B.; Buhse, M.; Zarif, M.; Blitz, K.; Sergott, R.; Gudesblatt, M.
ISI:000413730203253
ISSN: 1352-4585
CID: 5343592
Switching to natalizumab is associated with improvements in cognitive function as measured by NeuroTrax [Meeting Abstract]
Gudesblatt, M.; Wissemann, K.; Zarif, M.; Bumstead, B.; Fafard, L.; Wilken, J.; Blitz, K.; Buhse, M.; Dong, Q.; Hotermans, C.; Walsh, J.; Lee, L.
ISI:000413730204112
ISSN: 1352-4585
CID: 5343602